Literature DB >> 14557558

Possible phenotypic dosage effect in patients compound heterozygous for FSHD-sized 4q35 alleles.

M Wohlgemuth1, R J Lemmers, E L van der Kooi, M J van der Wielen, P G van Overveld, H Dauwerse, E Bakker, R R Frants, G W Padberg, S M van der Maarel.   

Abstract

OBJECTIVE: Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) is associated with a contraction of the D4Z4 repeat array on chromosome 4. So far, homozygosity or compound heterozygosity for FSHD alleles has not been described, and it has been debated whether the absence of such subjects is because of the rarity or the lethality of the disorder.
METHODS: Two unrelated families in which the probands are compound heterozygous for two FSHD-sized alleles were studied. Clinical examination, pulsed-field gel electrophoresis (PFGE) studies of DNA with probes proximal and distal to D4Z4, and cytogenetic analysis of metaphase chromosomes by FISH were performed.
RESULTS: Complementary molecular and cytogenetic approaches confirmed the chromosome 4qA origin of all FSHD-sized repeat arrays that segregate in the families.
CONCLUSIONS: Heterozygosity for FSHD-sized alleles is compatible with life in men and women. A possible dosage effect was observed in both probands in whom each 4qA allele contributed to the FSHD phenotype. Because at least one of the FSHD alleles in both families showed an unusual low penetrance, the authors propose that susceptibility for FSHD is partly determined by intrinsic properties of the disease allele other than the residual D4Z4 repeat size alone.

Entities:  

Mesh:

Year:  2003        PMID: 14557558     DOI: 10.1212/wnl.61.7.909

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

1.  Chromatin loop domain organization within the 4q35 locus in facioscapulohumeral dystrophy patients versus normal human myoblasts.

Authors:  Andrei Petrov; Iryna Pirozhkova; Gilles Carnac; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy.

Authors:  Richard J F L Lemmers; Mariëlle Wohlgemuth; Rune R Frants; George W Padberg; Eva Morava; Silvere M van der Maarel
Journal:  Am J Hum Genet       Date:  2004-10-04       Impact factor: 11.025

3.  Clinical features of facioscapulohumeral muscular dystrophy 2.

Authors:  J C de Greef; R J L F Lemmers; P Camaño; J W Day; S Sacconi; M Dunand; B G M van Engelen; S Kiuru-Enari; G W Padberg; A L Rosa; C Desnuelle; S Spuler; M Tarnopolsky; S L Venance; R R Frants; S M van der Maarel; R Tawil
Journal:  Neurology       Date:  2010-10-26       Impact factor: 9.910

Review 4.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

5.  Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy.

Authors:  Isabella Scionti; Francesca Greco; Giulia Ricci; Monica Govi; Patricia Arashiro; Liliana Vercelli; Angela Berardinelli; Corrado Angelini; Giovanni Antonini; Michelangelo Cao; Antonio Di Muzio; Maurizio Moggio; Lucia Morandi; Enzo Ricci; Carmelo Rodolico; Lucia Ruggiero; Lucio Santoro; Gabriele Siciliano; Giuliano Tomelleri; Carlo Pietro Trevisan; Giuliana Galluzzi; Woodring Wright; Mayana Zatz; Rossella Tupler
Journal:  Am J Hum Genet       Date:  2012-04-06       Impact factor: 11.025

6.  Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy.

Authors:  Richard J L F Lemmers; Marielle Wohlgemuth; Kristiaan J van der Gaag; Patrick J van der Vliet; Corrie M M van Teijlingen; Peter de Knijff; George W Padberg; Rune R Frants; Silvere M van der Maarel
Journal:  Am J Hum Genet       Date:  2007-09-07       Impact factor: 11.025

7.  A nuclear matrix attachment site in the 4q35 locus has an enhancer-blocking activity in vivo: implications for the facio-scapulo-humeral dystrophy.

Authors:  Andrei Petrov; Jeanne Allinne; Iryna Pirozhkova; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  Genome Res       Date:  2007-11-21       Impact factor: 9.043

8.  Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.

Authors:  Takako Iida Jones; Jennifer C J Chen; Fedik Rahimov; Sachiko Homma; Patricia Arashiro; Mary Lou Beermann; Oliver D King; Jeffrey B Miller; Louis M Kunkel; Charles P Emerson; Kathryn R Wagner; Peter L Jones
Journal:  Hum Mol Genet       Date:  2012-07-13       Impact factor: 6.150

9.  Counseling and prenatal diagnosis in facioscapulohumeral muscular dystrophy: A retrospective study on a 13-year multidisciplinary approach.

Authors:  Maria Francesca Di Feo; Cinzia Bettio; Valentina Salsi; Emma Bertucci; Rossella Tupler
Journal:  Health Sci Rep       Date:  2022-04-20

10.  The Facioscapulohumeral muscular dystrophy region on 4qter and the homologous locus on 10qter evolved independently under different evolutionary pressure.

Authors:  Monica Rossi; Enzo Ricci; Luca Colantoni; Giuliana Galluzzi; Roberto Frusciante; Pietro A Tonali; Luciano Felicetti
Journal:  BMC Med Genet       Date:  2007-03-02       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.